Roivant Sciences (NASDAQ:ROIV – Get Free Report) and Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.
Analyst Ratings
This is a breakdown of recent ratings for Roivant Sciences and Agios Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Roivant Sciences | 1 | 1 | 10 | 1 | 2.85 |
| Agios Pharmaceuticals | 1 | 4 | 5 | 1 | 2.55 |
Roivant Sciences presently has a consensus target price of $37.68, suggesting a potential downside of 9.25%. Agios Pharmaceuticals has a consensus target price of $41.25, suggesting a potential upside of 22.71%. Given Agios Pharmaceuticals’ higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Roivant Sciences.
Volatility and Risk
Profitability
This table compares Roivant Sciences and Agios Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Roivant Sciences | -3,534.96% | -22.94% | -21.53% |
| Agios Pharmaceuticals | -418.24% | -35.67% | -33.06% |
Valuation & Earnings
This table compares Roivant Sciences and Agios Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Roivant Sciences | $8.26 million | 3,630.93 | -$299.77 million | ($0.53) | -78.34 |
| Agios Pharmaceuticals | $54.03 million | 37.14 | -$412.78 million | ($7.01) | -4.80 |
Roivant Sciences has higher earnings, but lower revenue than Agios Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
64.8% of Roivant Sciences shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Roivant Sciences beats Agios Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
